PMS-SILDENAFIL TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
24-08-2016
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
SILDENAFIL (SILDENAFIL CITRATE)
제공처:
PHARMASCIENCE INC
ATC 코드:
G04BE03
INN (International Name):
SILDENAFIL
복용량:
25MG
약제 형태:
TABLET
구성:
SILDENAFIL (SILDENAFIL CITRATE) 25MG
관리 경로:
ORAL
패키지 단위:
4
처방전 유형:
Prescription
치료 영역:
PHOSPHODIESTERASE TYPE 5 INHIBITORS
제품 요약:
Active ingredient group (AIG) number: 0136261001; AHFS:
승인 상태:
APPROVED
승인 날짜:
2012-11-13
제품 특성 요약
PRODUCT MONOGRAPH
PR PMS-SILDENAFIL
Sildenafil tablets (as sildenafil citrate)
25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave., Suite 100
August 9, 2016
Montreal, Quebec
H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO: 196963
_ _
_ _
_pms-SILDENAFIL Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT
INFORMATION.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................
13
DOSAGE AND ADMINISTRATION
..........................................................................................
16
OVERDOSAGE
.............................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
18
STORAGE AND STABILITY
......................................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
21
DOSAGE FORMS, COMPOSITION AND
PACKAGING.......................................................... 21
PART II: SCIENTIFIC INFORMATION
..............
전체 문서 읽기
